Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Earlier Attention To REMS Could Keep Drug Approvals On Schedule, Industry Says At FDA Meeting

This article was originally published in The Pink Sheet Daily

Executive Summary

BIO member survey finds 77 percent of firms with REMS report that risk discussions prolonged product reviews.
Advertisement

Related Content

PhRMA Wants MedGuides Developed The Pre-FDAAA Way, Not Through REMS
PhRMA Wants MedGuides Developed The Pre-FDAAA Way, Not Through REMS
FDA Seeks To Write MedGuides Outside REMS Process
FDA Seeks To Write MedGuides Outside REMS Process
FDA Seeks To Write MedGuides Outside REMS Process
FDA Seeks To Write MedGuides Outside REMS Process
PDUFA V Discussions To Begin With April 12 Meeting
PDUFA V Discussions To Begin With April 12 Meeting
Regulatory Updates, In Brief

Topics

Advertisement
UsernamePublicRestriction

Register

PS070472

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel